This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Badie, B., Kramar, M.H., Lau, R., Boothman, D.A., Economou, J.S., and Black, K.L., 1998, Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors, J. Neurooncol.37:217–222.
Bakalkin, G., Selivanova. G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K.P., Szekely, L., Klein, G., Terenus, L., and Wiman, K.G., 1995, p53 binds single stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain, Nucl. Acids Res.23:362–269.
Barret, J.M., and Hill, B.T., 1998, DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets, Anticancer Drugs9:105–123.
Binetruy, B., Smeal, T., and Karin, M., 1991, Ha-ras augments c-Jun activity and stimulates phosphorylation of its activation domain, Nature351:122–127.
Cavigelli, M., Dolfi, F., Claret, F.X., and Karin, M., 1995, Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation, EMBO J.14:5957–5964.
Chelliah, J., and Jarvis, W.D., 1996, Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67), Cell Growth Differ.7:603–613.
Clarke, A.R., Purdie, C.A., and Harrison, D.J., et al., 1993, Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature362:849–852.
Crooke, S.T., 1992, Therapeutic applications of oligonucleotides, Annu. Rev. Pharmacol. Toxicol.32:329–376.
Crooke, ST., 1998, Molecular mechanisms of antisense drugs: Rnase H, Antisense Nucleic Acid Drug Dev.8:133–134.
Crul, M., Schellens, J.H., Beijnen, J.H., and Maliepaard, M., 1997, Cisplatin resistance and DNA repair, Cancer Treat Rev.23:341–366.
Dean, N.M., McKay, R., Miraglia, L., Geiger, T., Muller, M., Fabbro, D., and Bennett, C.F., 1996, Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents, Biochem. Soc. Trans.24:623–629.
De Luca, L.G., Johnson, D.R., Whitley, M.Z., Collins, T., and Pober, J.S., 1994, cAMP and tumor necrosis factor competitively regulated transcriptional activation through a nuclear factor binding to the cAMP-responsive element/activating transcription fact element of the endothelial leukocyte adhesion molecule-1 (E-selectin) promoter, J. Biol. Chem.269:19193–19196.
Derijard, B., Hibi, M., Wu, I.H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R.J., 1994, JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain, Cell76:1025–1037.
Dorigo, O., Turla, S.T., Lebedeva, S., and Gjerset, R.A., 1998, Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function, J. Neurosurg.88:535–540.
Fink, D., Aebi, S., Howell, S.B., 1998, The role of DNA mismatch repair in drug resistance, Clin. Cancer Res.4:1–6.
Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Zhang, W.W., Owen-Schaub, L.B., and Roth, J.A., 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res.54:2287–2291.
Funato, T., Yoshida, E., Jiao, L., Tone, T., Kashani-Sabet, M., and Scanlon, K.J., 1992, The utility of an antifos ribozyme in reversing cisplatin resistance in human carcinomas, Adv. Enzyme Regul.32:195–209.
Gjerset, R.A., Turla, S.T., Sobol, R.E., Scalise, J.J., Mercola, D., Collins, H., Hopkins, and P.J., 1995, Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Molec. Carcinog.14:275–285.
Gjerset, R.A., Dorigo, O., and Maung, V., et al., 1997, Tumor regression in vivo following p53 combination therapy, Cancer Gene Therapy4:0–2.
Grant, S., Freemerman, A.J., Birrer, M.J., Martin, H.A., Turner, A.J., Szabo, E., and Reed, E., 1998, Platinum-DNA adduct, nucelotide excision repair and platinum based anti-cancer chemotherapy, Cancer Treat Rev.24:331–344.
Gupta, S., Campbell, D., Derijard, B., and Davis, R.J., 1995, Transcription factor ATF2 regulation by the JNK signal transduction pathway, Science267:389–393.
Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M., 1993, Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain, Genes Dev.7:2135–2148.
Jennerwein, M.M., and Eastman, A., 1991, A polymerase chain reaction-based method to detect cisplatin adducts in specific genes, Nucleic Acids Res.19:6209–6214.
Lee, S., Elenbas, B., Levine, A., and Griffith, J., 1995, p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches, Cell81:1013–1021.
Levine, A.J., 1993, The tumor suppressor genes, Annu. Rev. Biochem.62:623–651.
Levine, A.J., 1997, p53, the cellular gatekeeper for growth and division, Cell88:323–331.
Livingstone, C., Patel, G., and Jones, N., 1995, ATF-2 contains a phosphorylation-dependent transcriptional activation domain, EMBO J.14:1785–1797.
Lotem, J., and Sachs, L., 1993, Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents, Blood82:1092–1096.
Lowe, S.W., Ruley, H.E., and Jacks, T., and Housman, D.E., 1993, p53-mediated apoptosis modulates the cytotoxicity of anti-cancer agents, Cell74:957–967.
Lowe, S.W., Bodis, S., McClatchy A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E., and Jacks, T., 1994, p53 status and the efficacy of cancer therapy in vivo, Science266:807–810.
McKay, R.A., Miraglia, L.J., Cummins, L.L., Owens, S.R., Sasmor, H., and Dean, N.M., Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression, J. Biol. Chem.274:1715–1722.
Miyake, H., Hara, I., Gohji, K., Yamanaka, K., Arakawa, S., and Kamidono, S., 1998, Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer, Anticancer Res.18:3087–3092.
Newell, C.L., Deisseroth, A.B., and Lopez-Berestein, G., 1994, Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene, J. Leukocyte Biol.56:27–35.
Nguyen, D.M., Spitz, F.R., Yen, N., Cristiano, R.J., and Roth, J.A., 1996, Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer, J. Thorac. Cardiovasc. Surg.112:1372–1376, discussion 1376–1377.
Nielsen, L.L., Lipari, P., Dell, J., Gurnani, M., and Hajian, G., 1998, Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer, Clin. Cancer Res.4:835–846.
O’Connor, P.M., Jackman, J., Bae, I., Myers, T.G., Fan, S., Mutoh, M., Scuderio, D.A., Monks, A., Sausville, E.A., Weinstein, J.N., Friend, S., Fornace, A.J., Jr., and Kohn, K.W., 1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res., 57:4285–4300.
Oshita, F., and Saijo, N., 1994, Rapid polymerase chain reaction assay to detect variation in the extent of genespecific damage between cisplatin-or VP-16-resistant and sensitive lung cancer cell lines, Jpn J. Cancer Res.85:669–673.
Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M.J., Gjerset, R., and Mercola, D., 1997, The JNK/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin, J. Biol. Chem.272:14041–14044.
Potapova, O., Bost, F., Dean, N., and Mercola, D., 1998, Inhibition of the JNK pathway blocks cell cycle progression in human tumor cells, Proc. AACR, 89th Annual Meeting, abstract #1720, p. 251.
Reed, E., 1998, Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy, Cancer Treatment Reviews24: 331–344.
Roth, J.A., Swisher, S.G., Merritt, J.A., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., EI-Naggar, A.K., Fossella, F.V., Glisson, B.S., Hong, W.K., Khurl, F.R., Kurie, J.M., Nesbitt, J.C., Pisters, K., Putnam, J.B., Schrump, D.S., Shin, D.M., and Walsh, G.L.,1998, Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement, Semin. Oncol.25:33–37.
Saves, I., and Masson, J.M., 1998, Mechanisms of resistance to xenobiotics in human therapy, Cell Mol Life Sci.54:405–426.
Scanlon, K.J., Kashani-Sabet, M., 1988, Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells, Proc. Natl. Acad. Sci. USA.85:650–653.
Scanlon, K.J., Kashani-Sabet, M., Miyachi, H., Sowers, L.C., and Rossi, J., 1989, Molecular basis of cisplatin resistance in human carcinomas: model systems and patients, Anticancer Res.9:1301–1312.
Scanlon, K.J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M., 1991, Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein, Proc. Natl. Acad. Sci. USA.88:10591–10595.
Smeal, T., Binetruy, B., Mercola, D., Birrer, M., and Karin, M., 1991, Oncogenic and transcriptional co-operation with Ha-ras requires phosphorylation of c-Jun on serines 63 and 73, Nature354:494–496.
Smeal, T., Binetruy, B., Mercola, D., Grover-Bardwick, A., Heidecker, G., Rapp, U.R., and Karin, M., 1992, Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73, Mol. Cell. Biol.12:3507–3513.
Stark, G.R., 1993, Regulation and mechanisms of mammalian gene amplification. Adv. Cancer Res.61:87–113.
Stein, C.A., and Kreig, A.M., 1994, Problems in interpretation of data derived from in vitro and in vivo use of antisence oligodeoxynucleotides, Antisense Res. Dev.4:67–69.
Van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P., and Angel, P., 1995, ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents, EMBO J.14:1798–1811.
Wilhelm, D., van Dam, H., Herr, I., Baumann, B., Herrlich, P., and Angel, P., 1995, Both ATP-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation, Immunobiology193:143–148.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Gjerset, R.A., Mercola, D. (2002). Sensitization of Tumors to Chemotherapy Through Gene Therapy. In: Habib, N.A. (eds) Cancer Gene Therapy. Advances in Experimental Medicine and Biology, vol 465. Springer, New York, NY. https://doi.org/10.1007/0-306-46817-4_24
Download citation
DOI: https://doi.org/10.1007/0-306-46817-4_24
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46191-0
Online ISBN: 978-0-306-46817-9
eBook Packages: Springer Book Archive